|  View printer-friendly version | | << Back | | MDRNA, Inc. to Hold Year-End 2008 Earnings Conference on Tuesday, March 24, 2009, at 8:30 a.m. Eastern Time | | BOTHELL, WA, Mar 20, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a
conference call with investors and security analysts on Tuesday,
March 24, 2009, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to
discuss financial results for the fourth quarter and fiscal year
ended December 31, 2008. To participate in the live conference call,
U.S. residents should dial 866-356-4441 and international callers
should dial 617-597-5396. The participant code for the live
conference call is 88132749. To access the 24-hour telephone replay,
U.S. residents should dial 888-286-8010 and international callers
should dial 617-801-6888. The participant code for the replay is
27372871.
Alternatively, to access the live audio webcast for this conference
call, please go to MDRNA's Web site at http://www.mdrnainc.com
approximately 15 minutes prior to the conference call in order to
register and download any necessary software. A replay of the webcast
will be available for 30 days following the event.
About MDRNA, Inc.
MDRNA is a biotechnology company focused on the development and
commercialization of therapeutic products based on RNA interference
(RNAi). Our goal is to improve human health by combining novel
RNAi-based compounds and proprietary peptide- and liposomal-based
drug delivery technologies to provide superior therapeutic options.
Our multi-disciplinary portfolio of capabilities includes molecular
biology, cellular biology, formulation expertise, peptide and
alkylated amino acid chemistry, pharmacology, toxicology and
bioinformatics. We are applying this expertise to a single,
integrated drug discovery platform that will be the engine for our
clinical pipeline and a versatile platform for establishing broad
therapeutic partnerships. We are also building on new technologies,
such as UsiRNAs that incorporate the non-nucleotide moiety Unlocked
Nucleobase Analog (UNA) within the siRNA molecule, that we expect to
lead to safer and more effective RNAi-based therapeutics. By
combining broad expertise in siRNA science with proven delivery
platforms and a strong and growing IP position, MDRNA is well
positioned as a leading RNAi therapeutics company and value-added
collaborator for our research partners. Additional information about
MDRNA, Inc. is available at http://www.mdrnainc.com.
Contact:
Matthew D. Haines
Senior Director, Investor Relations and Corporate Communications
(212) 209-3874
Email Contact
SOURCE: MDRNA, Inc.
http://www2.marketwire.com/mw/emailprcntct?id=A45D9713F3921B82
|
 |
|
 |  |
